Making It Personal: Neoantigen Vaccines in Metastatic Melanoma Matthew D. Hellmann, Alexandra Snyder Immunity Volume 47, Issue 2, Pages 221-223 (August 2017) DOI: 10.1016/j.immuni.2017.08.001 Copyright © 2017 Elsevier Inc. Terms and Conditions
Figure 1 Key Questions Remain Following initial reports demonstrating safety and promising signals of efficacy for neoantigen vaccines, important questions for the field include how to expedite vaccine production for feasible administration in the context of metastatic disease; optimizing schedules, administration, and adjuvants for vaccination; exploring rational combinations with other immunotherapies; expanding clinical scenarios; and perhaps most critically, improving the understanding of what features makes an optimal neoantigen target for vaccination. Immunity 2017 47, 221-223DOI: (10.1016/j.immuni.2017.08.001) Copyright © 2017 Elsevier Inc. Terms and Conditions